Do you have the same question? Follow this Question
May 13, 2026 - 08:41 AM
We’ve provided several answers to questions related to Vastarel MR (Trimetazidine) , see some other helpful Q&A related to this product.
Question: What are the common side effects of Vastarel?
Answer: Common side effects of Vastarel (trimetazidine) include dizziness, headache, abdominal pain, nausea, and vomiting. Some patients may also experience skin rashes or itching. Serious side effects are rare but may include movement disorders such as tremors or unsteady walking.
Question: What is the ChEBI identifier for this medication?
Answer: The ChEBI identifier is CHEBI:322963. ChEBI (Chemical Entities of Biological Interest) IDs are useful for academic and scientific research on the compound.
Question: What regulatory agency has licensed this medication?
Answer: It is licensed by the European Medicines Agency (EMA). EMA approval means the medication meets strict European standards for safety and effectiveness.
Question: What percentage of the drug binds to protein?
Answer: The protein binding is 16%. Lower protein binding can mean more free drug in the bloodstream, which can be important for how the medication works and interacts with other drugs.
Question: What is the route of administration?
Answer: The route of administration is oral. Oral administration is convenient and non-invasive, making it easy for most patients to take regularly.
Question: What is the active ingredient in this product?
Answer: The active ingredient is trimetazidine. Trimetazidine helps protect the heart by optimizing its energy use, which is particularly valuable for people with angina.
